284 related articles for article (PubMed ID: 32128409)
21. Hutchinson-Gilford Progeria Syndrome-Current Status and Prospects for Gene Therapy Treatment.
Piekarowicz K; Machowska M; Dzianisava V; Rzepecki R
Cells; 2019 Jan; 8(2):. PubMed ID: 30691039
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of angiogenic incompetence in Hutchinson-Gilford progeria via downregulation of endothelial NOS.
Gete YG; Koblan LW; Mao X; Trappio M; Mahadik B; Fisher JP; Liu DR; Cao K
Aging Cell; 2021 Jul; 20(7):e13388. PubMed ID: 34086398
[TBL] [Abstract][Full Text] [Related]
23. Genetic reduction of mTOR extends lifespan in a mouse model of Hutchinson-Gilford Progeria syndrome.
Cabral WA; Tavarez UL; Beeram I; Yeritsyan D; Boku YD; Eckhaus MA; Nazarian A; Erdos MR; Collins FS
Aging Cell; 2021 Sep; 20(9):e13457. PubMed ID: 34453483
[TBL] [Abstract][Full Text] [Related]
24. A new fluorescent probe for the visualization of progerin.
Macicior J; Fernández D; Ortega-Gutiérrez S
Bioorg Chem; 2024 Jan; 142():106967. PubMed ID: 37979321
[TBL] [Abstract][Full Text] [Related]
25. Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.
Kang SM; Yoon MH; Ahn J; Kim JE; Kim SY; Kang SY; Joo J; Park S; Cho JH; Woo TG; Oh AY; Chung KJ; An SY; Hwang TS; Lee SY; Kim JS; Ha NC; Song GY; Park BJ
Commun Biol; 2021 Jan; 4(1):5. PubMed ID: 33398110
[TBL] [Abstract][Full Text] [Related]
26. Progerin-Induced Replication Stress Facilitates Premature Senescence in Hutchinson-Gilford Progeria Syndrome.
Wheaton K; Campuzano D; Ma W; Sheinis M; Ho B; Brown GW; Benchimol S
Mol Cell Biol; 2017 Jul; 37(14):. PubMed ID: 28483909
[TBL] [Abstract][Full Text] [Related]
27. Unique progerin C-terminal peptide ameliorates Hutchinson-Gilford progeria syndrome phenotype by rescuing BUBR1.
Zhang N; Hu Q; Sui T; Fu L; Zhang X; Wang Y; Zhu X; Huang B; Lu J; Li Z; Zhang Y
Nat Aging; 2023 Feb; 3(2):185-201. PubMed ID: 37118121
[TBL] [Abstract][Full Text] [Related]
28. Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA gene mutations.
Gonzalo S; Kreienkamp R; Askjaer P
Ageing Res Rev; 2017 Jan; 33():18-29. PubMed ID: 27374873
[TBL] [Abstract][Full Text] [Related]
29. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.
Strandgren C; Revêchon G; Sola-Carvajal A; Eriksson M
Biochem Soc Trans; 2017 Dec; 45(6):1279-1293. PubMed ID: 29127216
[TBL] [Abstract][Full Text] [Related]
30. Metformin decreases progerin expression and alleviates pathological defects of Hutchinson-Gilford progeria syndrome cells.
Egesipe AL; Blondel S; Lo Cicero A; Jaskowiak AL; Navarro C; Sandre-Giovannoli A; Levy N; Peschanski M; Nissan X
NPJ Aging Mech Dis; 2016; 2():16026. PubMed ID: 28721276
[TBL] [Abstract][Full Text] [Related]
31. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
32. Anti-hsa-miR-59 alleviates premature senescence associated with Hutchinson-Gilford progeria syndrome in mice.
Hu Q; Zhang N; Sui T; Li G; Wang Z; Liu M; Zhu X; Huang B; Lu J; Li Z; Zhang Y
EMBO J; 2023 Jan; 42(1):e110937. PubMed ID: 36382717
[TBL] [Abstract][Full Text] [Related]
33. Exacerbated atherosclerosis in progeria is prevented by progerin elimination in vascular smooth muscle cells but not endothelial cells.
Benedicto I; Carmona RM; Barettino A; Espinós-Estévez C; Gonzalo P; Nevado RM; de la Fuente-Pérez M; Andrés-Manzano MJ; González-Gómez C; Rolas L; Dorado B; Nourshargh S; Hamczyk MR; Andrés V
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2400752121. PubMed ID: 38648484
[TBL] [Abstract][Full Text] [Related]
34. iPSC-Derived Endothelial Cells Affect Vascular Function in a Tissue-Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome.
Atchison L; Abutaleb NO; Snyder-Mounts E; Gete Y; Ladha A; Ribar T; Cao K; Truskey GA
Stem Cell Reports; 2020 Feb; 14(2):325-337. PubMed ID: 32032552
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review.
Arancio W; Pizzolanti G; Genovese SI; Pitrone M; Giordano C
Gerontology; 2014; 60(3):197-203. PubMed ID: 24603298
[TBL] [Abstract][Full Text] [Related]
36. Pluripotent stem cells to model Hutchinson-Gilford progeria syndrome (HGPS): Current trends and future perspectives for drug discovery.
Lo Cicero A; Nissan X
Ageing Res Rev; 2015 Nov; 24(Pt B):343-8. PubMed ID: 26474742
[TBL] [Abstract][Full Text] [Related]
37. Endothelial progerin expression causes cardiovascular pathology through an impaired mechanoresponse.
Osmanagic-Myers S; Kiss A; Manakanatas C; Hamza O; Sedlmayer F; Szabo PL; Fischer I; Fichtinger P; Podesser BK; Eriksson M; Foisner R
J Clin Invest; 2019 Feb; 129(2):531-545. PubMed ID: 30422822
[TBL] [Abstract][Full Text] [Related]
38. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
McClintock D; Gordon LB; Djabali K
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
[TBL] [Abstract][Full Text] [Related]
39. An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.
Harhouri K; Frankel D; Bartoli C; Roll P; De Sandre-Giovannoli A; Lévy N
Nucleus; 2018 Jan; 9(1):246-257. PubMed ID: 29619863
[TBL] [Abstract][Full Text] [Related]
40. Splicing-directed therapy in a new mouse model of human accelerated aging.
Osorio FG; Navarro CL; Cadiñanos J; López-Mejía IC; Quirós PM; Bartoli C; Rivera J; Tazi J; Guzmán G; Varela I; Depetris D; de Carlos F; Cobo J; Andrés V; De Sandre-Giovannoli A; Freije JM; Lévy N; López-Otín C
Sci Transl Med; 2011 Oct; 3(106):106ra107. PubMed ID: 22030750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
